Abstract
Baseline PSMA PET-CT is prognostic for treatment failure in men with intermediate-to-high risk prostate cancer: 54 months follow-up of the proPSMA randomised trial
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have